UBS Group
CLBT icon

UBS Group’s Cellebrite CLBT Stock Holding History

UBS Group’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-402,000
Closed -$3.72M – 10291
2021
Q3 		$3.72M Buy
+402,000
New +$4.2M ﹤0.01% 2984

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.37B AUM 36.36% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group's CLBT Position: Q1 2026 in Review

UBS Group increased its Cellebrite (CLBT) stake by 51% in Q1 2026, buying an estimated $2.92M and bringing the position to 570,148 shares worth $7.86M. The position accounts for ﹤0.01% of the portfolio, ranked #3612.

UBS Group first reported a position in CLBT in Q3 2021 and has held it in 15 quarters since. The position peaked at $14.4M in Q1 2025. 220 funds tracked by Wall St. Rank hold CLBT as of Q1 2026.

  • UBS Group held 570,148 shares of Cellebrite worth $7.86M as of Q1 2026.
  • UBS Group bought 193,772 Cellebrite shares in Q1 2026, an estimated $2.92M.
  • Cellebrite made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3612 holding.
  • UBS Group first reported a position in Cellebrite in Q3 2021 and has held it in 15 quarters since.
  • UBS Group's Cellebrite position peaked at $14.4M in Q1 2025.
  • 220 funds tracked by Wall St. Rank held Cellebrite as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.